Actively Recruiting
Cannabidiol and Cannabis Concentrate Users
Led by University of Colorado, Denver · Updated on 2026-05-01
120
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
Sponsors
U
University of Colorado, Denver
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a randomized, placebo-controlled, dose-ranging trial of plant-derived cannabidiol (CBD) among people who regularly use cannabis concentrates but are not trying to stop or cut down on their use. The main questions it aims to answer are whether CBD, relative to placebo, reduces cannabis concentrate use, the subjective effects of cannabis, or cannabis craving. Participants will take CBD (200 mg or 400 mg per day) or placebo for 4 weeks and will complete three visits during the study medication period, all conducted using a mobile laboratory.
CONDITIONS
Official Title
Cannabidiol and Cannabis Concentrate Users
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 25-60.
- Regular use (at least 4 times per week) of cannabis concentrates for the last year.
- Not currently seeking to cut down or stop cannabis use.
- At least one episode of 3 consecutive days of cannabis abstinence with no severe withdrawal symptoms in the last 90 days.
- At least two symptoms of a DSM-5 cannabis use disorder.
You will not qualify if you...
- Use of any illicit substance besides alcohol, nicotine, or cannabis in the past 60 days.
- Use of CBD-containing products other than cannabis concentrates in the past 90 days.
- Alcohol use on 3 or more days per week, or more than 3 drinks per drinking day in the past 60 days.
- Breath alcohol level above 0 at study visits.
- Daily nicotine use.
- Diagnosis or history of psychotic disorders, bipolar disorder, or major depression with suicidal ideation.
- Current cardiovascular or respiratory disease.
- Use of psychotropic or hepatotoxic medications.
- Use of anti-epileptic medications or medications interacting with Epidiolex, or history of seizures.
- Use of strong or moderate CYP3A4 or CYP2C19 inhibitors or inducers.
- Current or past liver disease indicated by medical history or liver enzyme levels.
- Pregnancy, trying to become pregnant, or lactating for female participants.
- Not willing to use approved birth control if of childbearing potential.
- Current suicidality risk as assessed during study screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
J
Joseph P Schacht, PhD
CONTACT
K
Kristen M Raymond, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here